Atara Biotherapeutics(ATRA)
Search documents
Atara Biotherapeutics(ATRA) - 2019 Q2 - Earnings Call Transcript
2019-08-09 04:04
Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Q2 2019 Results Earnings Conference Call August 8, 2018 8:00 AM ET Company Participants John Craighead - Vice President of Investor Relations and Corporate Communications Pascal Touchon - President and Chief Executive Officer AJ Joshi - Chief Medical Officer Chris Haqq - Chief Scientific Officer Conference Call Participants Anupam Rama - JP Morgan John Newman - Canaccord Genuity Salim Syed - Mizohu Americas Matt Phipps - William Blair Philip Nadeau - Cowen and C ...
Atara Biotherapeutics(ATRA) - 2019 Q2 - Quarterly Report
2019-08-08 11:51
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36548 ATARA BIOTHERAPEUTICS, INC. (Exact name of Registrant as specified in its Charter) Delaware 46-0920988 (State or other jurisdiction of ...
Atara Biotherapeutics(ATRA) - 2019 Q1 - Quarterly Report
2019-05-09 12:25
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36548 | --- | --- | |------------------------------------------------------------------------------|--------------------------------------- ...
Atara Biotherapeutics(ATRA) - 2018 Q4 - Annual Report
2019-02-26 13:47
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36548 | --- | --- | |-------------------------------------------------------------------------------------------------|-------------- ...